Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E32.02 EPS (ttm)2.04 Insider Own0.04% Shs Outstand2.75B Perf Week1.93%
Market Cap179.93B Forward P/E15.60 EPS next Y4.19 Insider Trans-30.89% Shs Float2.75B Perf Month8.39%
Income5.69B PEG5.06 EPS next Q0.84 Inst Own74.90% Short Float0.67% Perf Quarter5.21%
Sales39.81B P/S4.52 EPS this Y30.60% Inst Trans-1.13% Short Ratio1.70 Perf Half Y4.31%
Book/sh15.68 P/B4.17 EPS next Y9.76% ROA- Target Price68.45 Perf Year34.68%
Cash/sh- P/C- EPS next 5Y6.33% ROE- 52W Range48.08 - 65.87 Perf YTD11.08%
Dividend1.88 P/FCF- EPS past 5Y0.20% ROI- 52W High-0.73% Beta0.82
Dividend %2.88% Quick Ratio- Sales past 5Y-3.70% Gross Margin65.50% 52W Low36.01% ATR1.04
Employees68000 Current Ratio- Sales Q/Q-1.00% Oper. Margin20.90% RSI (14)65.22 Volatility1.42% 1.40%
OptionableYes Debt/Eq- EPS Q/Q22.10% Profit Margin14.30% Rel Volume0.84 Prev Close65.26
ShortableYes LT Debt/Eq- EarningsFeb 02 BMO Payout89.50% Avg Volume10.79M Price65.39
Recom2.30 SMA203.27% SMA506.02% SMA2009.43% Volume9,048,256 Change0.20%
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Feb-20-17 09:03AM  [$$] Alzheimer's: Pharma's Great White Whale Is Still Worth Hunting at The Wall Street Journal
Feb-17-17 07:41PM  Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market
01:38PM  Clovis, Tesaro Soar on Astrazeneca Phase Three News
09:30AM  The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta
07:37AM  Prolia Expected to Be a Significant Growth Driver for Amgen in 2017
Feb-16-17 06:06PM  After-hours buzz: ANET, TRUE, MRK & more at CNBC
01:50PM  Merck HIV Drug Doravirine Reports Positive Results at Investopedia
11:18AM  Health Care ETF Has Been Ailing
09:31AM  What's Driving Lilly's (LLY) Shares after 2016 Decline?
09:27AM  Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
08:00AM  Mercks Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions Business Wire
Feb-15-17 09:14PM  DexCom Is a Great Healthcare Stock to Buy Now
07:34PM  Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next? at Motley Fool
04:40PM  Fossil and AIG slump, Procter & Gamble and Fortress jump
02:07PM  A breakthrough approach to treating Alzheimer's is facing major setbacks
02:00PM  Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
12:10PM  Merck Delivers Even More Disappointing News in Alzheimers Study
11:49AM  Warren Buffett's billion dollar bet on Apple stock
11:15AM  [$$] Merck's drug failure deals further blow to Alzheimer's theory at Financial Times
10:46AM  Merck Halts Late-Stage Alzheimers Drug Trial at Investopedia
10:42AM  Eli Lilly Is Great Stock to Buy Now
09:50AM  Dow Jones Closes at 20,504.41
08:29AM  Stocks to Watch: February 15, 2017
08:06AM  Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip
08:05AM  Early movers: PEP, ANTM, HLT, AMZN, GOOGL, IART & more at CNBC
07:00AM  Another Alzheimer's Drug Study Fails. This Time It's Merck's at Forbes
Feb-14-17 06:46PM  Merck stopping late stage study as another Alzheimer's drug fails Reuters
06:26PM  Merck Alzheimer's drug fails in 1 study; another continues
06:04PM  Merck to halt study of mild to moderate Alzheimer's drug Reuters
05:38PM  Merck Alzheimer's Drug Study Halted Early for Futility
05:22PM  Merck stops trial of Alzheimer's drug
05:15PM  Merck shares slip after hours as Alzheimer's study halted at MarketWatch
05:00PM  Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimers Disease to Stop for Lack of Efficacy Business Wire
04:05PM  Mercks Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial Business Wire
04:01PM  Apple, JPMorgan Dominate DJIA on Tuesday
03:10PM  Some of biotech's biggest names have acquired this Md. company at bizjournals.com
11:17AM  Gilead Sciences: Not Out of the Woods Yet? at Barrons.com
02:00AM  These drug and medical device companies made the most payments to N.Y.C. hospitals at bizjournals.com
Feb-13-17 04:24PM  Apple, Nike, Visa Among Dow's Top 5 Gainers So Far This Year
09:30AM  The Zacks Analyst Blog Highlights: Coca-Cola, Walt Disney, Visa, Boeing and Merck
Feb-11-17 12:05AM  [$$] Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion at The Wall Street Journal
Feb-10-17 05:41PM  Dow 30 Stock Roundup: Coca-Cola, Disney, Visa Beat on Earnings
01:10PM  Doylestown biopharm firm granted injunction over licensing dispute at bizjournals.com
12:00PM  Is More Downside Ahead For Teva Pharmaceutical? at Barrons.com
08:41AM  [$$] Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion at The Wall Street Journal
08:35AM  Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
06:44AM  Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
Feb-09-17 06:44PM  [$$] Bristol-Myers Squibb Stock in Bargain Bin at Barrons.com
12:45PM  Cramer: Here's the Reason for Allergan's Remarkable Run
09:00AM  Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care Business Wire
Feb-08-17 05:25PM  Nasdaq Reaches a New High on Wednesday
12:25PM  Merck's HPV Vaccine Gardasil May Hit Roadblock at Investopedia
11:39AM  Gilead Hepatitis C Meltdown Raises Troubling Question: Is Curing Disease Bad for Business?
Feb-07-17 05:22PM  Streamlined FDA Approval Process Would Boost Drug Makers
05:01PM  [$$] Gilead Posts Profit, Revenue Declines at The Wall Street Journal
04:42PM  Drug stocks dip after Spicer affirms Trumps stance on cutting costs at MarketWatch
02:07PM  Merck & Co., Inc. :MRK-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017
12:59PM  The FDA Accepts Keytruda From Merck & Co., Inc. (MRK) For Bladder Cancer at Insider Monkey
09:06AM  Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More
08:47AM  5 Stocks to Watch After the Market Closes Today
07:16AM  Better Buy: Merck & Co. Inc. vs. GlaxoSmithKline at Motley Fool
02:50AM  All eyes will be on Gileads hepatitis C franchise as it reports fourth-quarter earnings at MarketWatch
Feb-06-17 04:46PM  5 Stocks to Watch After the Market Closes Tomorrow
04:07PM  Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)
10:43AM  Merck & Co., Inc. :MRK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017
09:55AM  Q4 Earnings Faring Well for Pharma ETFs
09:30AM  The Zacks Analyst Blog Highlights: Apple, Exxon Mobil, Merck, Pfizer and Intel
08:19AM  Merck???s Keytruda Gets Priority Review for Bladder Cancer
Feb-04-17 06:41AM  Pfizer's New Biosimilar Is Off and Running at Motley Fool
Feb-03-17 09:30PM  Merck Marks World Cancer Day to Increase Awareness about Cancer Prevention through Social Media - Together We Can Prevent Cancer GlobeNewswire
05:28PM  Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC
04:59PM  Dow 30 Stock Roundup: Apple, Intel, Exxon Beat; Merck, Pfizer, Chevron Miss on Revenues
11:07AM  Merck Q4 Sales Slip, Promises Better 2017 at Investopedia
10:23AM  Merck's Sneak Peek Into Its Drug Pricing May Not Be Enough to Satisfy Skeptics at Motley Fool
10:09AM  Facebook Falls, Merck and Philip Morris Rise on Earnings Releases
07:38AM  Above the rise of Mercks Gardasil vaccine, a specter is looming at MarketWatch
06:45AM  FDA Accepts Two sBLAs for Mercks KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings Business Wire
Feb-02-17 05:33PM  Some CEOs advising Trump are job killers
05:32PM  Biogen: What Now? at Barrons.com
04:51PM  Biogen Trails Merck, Lilly In Alzheimer's; Hemophilia Spinoff Begins Trading
04:01PM  House Panel to Take Up Trump's Call to Speed FDA Approvals
03:49PM  Edited Transcript of MRK earnings conference call or presentation 2-Feb-17 1:00pm GMT
03:13PM  U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer Reuters
02:35PM  Pulling Back the Curtain on Danahers 4Q16 Operating Performance
01:11PM  Merck profit soars on new drugs, expects better 2017
01:05PM  [$$] AstraZeneca: faith healer at Financial Times
12:58PM  Lower Valuations Have Merck Looking 'Very Hard' at M&A Options
12:39PM  [$$] Merck Stock Rally Still Looks Healthy at The Wall Street Journal
12:00PM  Keytruda Helps Offset Generic Headwinds for Merck
11:06AM  Roche Bets on New Drugs to Boost Sales at Investopedia
10:54AM  Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales
10:17AM  Agilent (A) Announces Expanded Use of Diagnostic Assay
09:52AM  Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down
09:38AM  Stocks to Watch: Facebook, Mead Johnson, Ralph Lauren, Shutterfly at The Wall Street Journal
09:05AM  Why Mercks Q4 Earnings Arent Enough for Investors
08:57AM  Merck 2017 forecast eases concerns over royalty payments, dollar
08:32AM  Merck earnings stock gains give way after Keytruda revenue turns out to be a miss at MarketWatch
08:18AM  Merck (MRK) Tops Q4 Earnings, Misses Sales Estimates
08:01AM  Early movers: MRK, FB, BDX, CI, M, DLPH, EL & more at CNBC
07:11AM  Merck Posts In-Line 4Q Earnings, Issues Cautious 2017 Sales Outlook
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM